Autoimmune Conditions
Regenerative Medicine for Autoimmune Conditions
Autoimmune conditions share a common root: an immune system that has lost its ability to distinguish self from threat. Conventional treatment suppresses immunity broadly — reducing symptoms while increasing infection risk and long-term organ damage. WJ-MSC Exosome therapy takes a fundamentally different approach: restoring immune balance from within, without shutting the system down.
Multiple Sclerosis (MS)
The Problem
MS is a chronic autoimmune disease in which the immune system attacks myelin — the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin is destroyed, nerve signals slow or stop entirely, causing progressive disability: fatigue, spasticity, vision loss, cognitive impairment, and loss of motor function. Current disease-modifying therapies (DMTs) slow progression but do not repair existing damage, and many carry significant side effect profiles including increased cancer risk and opportunistic infections.
How WJ-MSC Exosomes Help
WJ-MSC Exosomes address MS through two parallel pathways. Immunomodulation: WJ-MSC Exosomes promote regulatory T cell (Treg) expansion and suppress Th17 activity — the primary autoimmune driver in MS. IDO and PGE2 secretion retrains immune tolerance to myelin antigens. Neuroprotection and Remyelination: WJ-MSC Exosomes secrete BDNF, NGF, and NT-3 — neurotrophic factors that protect surviving neurons and support oligodendrocyte precursor cells in remyelinating damaged axons. Clinical studies show stabilization of disability scores and, in some patients, measurable functional improvement.
Evidence Snapshot
- Llufriu S, et al. (2014). Randomized placebo-controlled phase II trial of autologous MSCs in MS. PLOS ONE. Demonstrated safety and reduction in new MRI lesions.
- Karussis D, et al. (2010). Safety and immunological effects of MSC transplantation in MS and ALS. Archives of Neurology. Showed Treg expansion and Th17 reduction following MSC infusion.
Lupus (Systemic Lupus Erythematosus)
The Problem
SLE is a systemic autoimmune disease that can affect virtually every organ — kidneys, joints, skin, heart, lungs, and brain. The immune system produces autoantibodies that attack the body’s own tissue, causing cycles of flare and remission. Lupus nephritis (kidney involvement) is a leading cause of morbidity. Standard treatment relies on hydroxychloroquine, corticosteroids, and immunosuppressants — all of which carry significant long-term toxicity.
How WJ-MSC Exosomes Help
WJ-MSC Exosomes have shown particular promise in lupus due to their powerful immunomodulatory profile. They suppress B cell hyperactivity (the source of autoantibodies), promote Treg expansion, reduce anti-dsDNA antibody titers, and decrease complement activation. In lupus nephritis specifically, WJ-MSC Exosomes reduce proteinuria and support renal tissue repair through paracrine signaling. Multiple clinical trials from Sun Yat-sen University have demonstrated sustained remission in refractory lupus patients following MSC infusion.
Rheumatoid Arthritis (RA)
The Problem
RA is a systemic autoimmune disease that primarily attacks the synovial lining of joints, causing progressive inflammation, cartilage destruction, bone erosion, and deformity. Unlike OA, RA is driven by immune dysregulation — T cells, B cells, and macrophages coordinate an attack on joint tissue. Biologics (TNF inhibitors, IL-6 blockers) have transformed RA management but fail to achieve remission in 30–40% of patients and carry risks of serious infection and malignancy.
How WJ-MSC Exosomes Help
WJ-MSC Exosomes address RA at the immune root. They suppress synovial macrophage activation, reduce TNF-α and IL-6 production, promote Treg expansion to restore self-tolerance, and inhibit osteoclast activity to protect bone from erosion. In joints already damaged, the same chondroprotective mechanisms that benefit OA patients apply — bFGF and TGF-β support cartilage matrix preservation. Clinical data shows significant reduction in DAS28 scores (disease activity) and CRP levels following MSC treatment.
Evidence Snapshot
- Wang L, et al. (2010). Allogeneic MSC transplantation in severe and refractory RA. Journal of Clinical Immunology. Demonstrated significant DAS28 reduction and sustained remission.
- Gonzalez MA, et al. (2009). Treatment of experimental arthritis by inducing immune tolerance with human adipose MSCs. Arthritis & Rheumatism. Confirmed Treg-mediated immune tolerance restoration.
Type 1 & Type 2 Diabetes
The Problem
Type 1 diabetes is an autoimmune condition in which the immune system destroys insulin-producing beta cells in the pancreatic islets. Type 2 diabetes involves progressive beta cell exhaustion combined with insulin resistance driven by chronic inflammation. Both result in impaired glucose regulation with devastating long-term complications: neuropathy, nephropathy, retinopathy, and cardiovascular disease. Current treatment manages blood sugar but does not restore beta cell function or address the underlying immune and inflammatory drivers.
How WJ-MSC Exosomes Help
For Type 1: WJ-MSC Exosomes suppress the autoimmune attack on beta cells through Treg promotion and Th1/Th17 suppression, while secreting hepatocyte growth factor (HGF) and EGF to support beta cell survival and regeneration. For Type 2: WJ-MSC Exosomes reduce systemic inflammation (TNF-α, IL-6) that drives insulin resistance, improve pancreatic microvascularization via VEGF, and support beta cell function restoration. Clinical trials show reductions in HbA1c, reduced insulin requirements, and improved C-peptide levels (a marker of endogenous insulin production) in both Type 1 and Type 2 patients.
Evidence Snapshot
- Hu J, et al. (2013). Long-term efficacy of umbilical cord MSCs for Type 2 diabetes. Endocrine Journal. Demonstrated sustained HbA1c reduction and improved beta cell function.
- Carlsson PO, et al. (2015). Preserved beta-cell function in Type 1 diabetes by MSC infusion. Diabetes. Showed C-peptide preservation and reduced insulin requirements following MSC treatment.
Immunomodulation vs. Immunosuppression: A Critical Distinction
This is one of the most important concepts to understand before pursuing any regenerative therapy.
Traditional immunosuppressive drugs (methotrexate, mycophenolate, cyclophosphamide, biologics) work by broadly reducing immune activity. They are effective at controlling symptoms but leave patients vulnerable to infection, malignancy, and organ toxicity with long-term use.
WJ-MSC Exosome therapy does not suppress immunity. Instead, it restores immune regulation — promoting the body’s own regulatory mechanisms (Tregs, tolerogenic dendritic cells) to distinguish self from threat more accurately. The immune system remains functional and protective. The autoimmune misfiring is corrected, not silenced.
This distinction matters clinically: patients on WJ-MSC Exosome therapy do not face the same infection risk profile as those on high-dose immunosuppressants. The goal is a recalibrated immune system, not a weakened one.
Safety Note
WJ-MSC Exosome therapy is additive to existing medications — not a replacement. Never discontinue or reduce your current autoimmune medications without explicit guidance from your prescribing physician. WJ-MSC Exosome therapy is designed to work alongside your existing treatment plan. Over time, as disease activity decreases, your rheumatologist or endocrinologist may choose to adjust your medications — but this decision must be made collaboratively and monitored carefully. Always inform all members of your care team that you are pursuing regenerative therapy.
Ready to Discuss Your Condition?
Autoimmune conditions are complex and highly individual. A consultation with Melissa will review your diagnosis, disease activity, current medications, and goals to determine whether WJ-MSC Exosome therapy is appropriate for your specific situation.